產(chǎn)品編號 | BIO0967SM |
英文名稱 | Anti-BCMA & CD3 Reference Antibody (Elranatamab Biosimilar) |
別 名 | TNFRSF17 / BCMA / CD269 & CD3; Elranatamab |
抗體來源 | |
克隆類型 | Monoclonal |
交叉反應(yīng) | Human |
產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
理論分子量 | 145.44kDa |
性 狀 | Lyophilized |
亞 型 | IgG-like |
純化方法 | Protein A |
緩 沖 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 |
保存條件 | -80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions;Avoid repeated freeze-thaw cycles. |
注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
PubMed | PubMed |
產(chǎn)品介紹 | |
產(chǎn)品圖片 |
Co-incubation of Elranatamab-Bcmm with Jurkat cells, then with the addition of huBCMA-HEK293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal.As shown in fig, Elranatamab-Bcmm was able to activate the NF-AT signaling pathway, and the EC50 was 0.081 nM.
Elranatamab-Bcmm bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Elranatamab-Bcmm bound to huCD3e-jurkat cells, and the EC50 was 64.990 nM.
Elranatamab-Bcmm bound to huBCMA-HEK293 cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Elranatamab-Bcmm bound to huBCMA-HEK293 cells, and the EC50 was 1.263 nM.
Elranatamab-Bcmm bound to BCMA protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Elranatamab-Bcmm bound to huBCMA-ECD-His , and the EC50 was 0.055 nM.
Anti-BCMA & CD3 Reference Antibody (Elranatamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
|
1、抗體溶解方法 | |
2、抗體修復(fù)方式 | |
3、常用試劑的配制 | |
4、免疫組化操作步驟 | |
5、免疫組化問題解答 | |
6、Western Blotting 操作步驟 | |
7、Western Blotting 問題解答 | |
8、關(guān)于肽鏈的設(shè)計 | |
9、多肽的溶解與保存 | |
10、酶標抗體效價測定程序 | |